Jinyu Bio-technology's (SHSE:600201) Soft Earnings Are Actually Better Than They Appear
Jinyu Bio-technology's (SHSE:600201) Soft Earnings Are Actually Better Than They Appear
Soft earnings didn't appear to concern Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) shareholders over the last week. Our analysis suggests that while the profits are soft, the foundations of the business are strong.
最近一周生物股份(SHSE:600201)的股东似乎并不担心营业收入较低。我们的分析表明,尽管利润较低,但企业的基础仍然坚实。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
To properly understand Jinyu Bio-technology's profit results, we need to consider the CN¥16m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Jinyu Bio-technology doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
要正确理解生物股份的盈利结果,我们需要考虑归因于飞凡项目的1600万人民币支出。看到飞凡项目导致公司利润下降并不是好事,但值得注意的是,情况可能会比预期好得多。我们研究了成千上万家上市公司,发现飞凡项目往往是一次性的。而且,这正是会计术语所暗示的。如果生物股份不再出现这些飞凡支出,其他条件相同的情况下,我们预计其利润将在未来一年内增加。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。
Our Take On Jinyu Bio-technology's Profit Performance
我们对生物股份的盈利表现看法
Unusual items (expenses) detracted from Jinyu Bio-technology's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Jinyu Bio-technology's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 3 warning signs for Jinyu Bio-technology you should be aware of.
飞凡项目(费用)在过去一年损害了生物股份的收入,但我们可能会在明年看到改善。根据这一观察,我们认为生物股份的法定利润实际低估了其盈利潜力!另一方面,过去十二个月,其每股收益实际上有所缩水。当然,我们在分析其收入方面只是触及了表面;人们还可以考虑利润率、预测增长和投资回报率等其他因素。要记住,在分析股票时,值得注意涉及到的风险。举例来说:我们已经发现了三个关于生物股份的警示信号,你应该注意。
This note has only looked at a single factor that sheds light on the nature of Jinyu Bio-technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
这份说明只关注了揭示生物股份利润性质的一个因素。但如果你能够将注意力集中在细枝末节上,总会有更多发现。例如,许多人认为高股本回报率是有利的商业经济迹象,而其他人则喜欢‘追踪资金’并寻找内部人员正在买入的股票。因此,你可能希望查看这个免费的高股本回报率公司收藏集,或这个高内部持股股票名单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。